$SGTX

Sigilon Therapeutics Inc

  • NASDAQ

PRICE

$0.6629 ▼-3.297%

Last Close

VOLUME

55,851

DAY RANGE

0.665 - 0.72

52 WEEK

0.68 - 6.91

Join Discuss about SGTX with like-minded investors

profile
@marketjay #Market Assassin Corp
recently

those were good continuation set ups, some names that I was looking at for this morning but have not developed a full report yet were IPA, BLZE, CB, JPM, MMM, MELI, EQIX, SIDU, SGTX

139 Replies 9 👍 11 🔥

profile
@dros #droscrew
recently

Upgrades 11/30: $AYLA $BXMT $CAJ $ESMT $HHR $KRP $MAG $PTR $SQ $TTE $ZM . Downgrades 11/30: $ABEO $CENT $CGC $CQP $DLTR $FLMN $GDP $SEDG $SGTX $STNE $STXB $TROX $VG

89 Replies 11 👍 7 🔥

Key Metrics

Market Cap

22.36 M

Beta

1.40

Avg. Volume

41.24 K

Shares Outstanding

32.40 M

Yield

0%

Public Float

0

Next Earnings Date

2022-11-03

Next Dividend Date

Company Information

Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates are non-viral engineered cell-based therapies designed to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, lysosomal disorders and diabetes. The engineered cells are protected by Sigilon’s Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.

Website:

HQ: ,

Related News